Table 1.
Characteristics of the study sample, by cohort
| Characteristic | STR (n=1797) |
2+PPD (n=5584) |
p Value | ||
|---|---|---|---|---|---|
| Age (mean (SD)) | 41.6 | (10.56) | 42.32 | (11.37) | 0.0137 |
| Gender (N, %) | |||||
| Male | 945 | 52.59 | 3063 | 54.85 | 0.1123 |
| Female | 852 | 47.41 | 2521 | 45.15 | 0.1439 |
| Race (N, %) | |||||
| White | 387 | 21.54 | 1221 | 21.87 | 0.8893 |
| Black | 1187 | 66.05 | 3658 | 65.51 | 0.6877 |
| Hispanic | 18 | 1.00 | 82 | 1.47 | 0.7844 |
| Other | 204 | 11.35 | 621 | 11.12 | 0.7846 |
| Unknown | 1 | 0.06 | 2 | 0.04 | 0.8766 |
| Basis of medicaid eligibility (N, %) | |||||
| Aged | 1 | 0.06 | 8 | 0.14 | 0.5634 |
| Disabled | 1089 | 60.60 | 4071 | 72.90 | <0.0001 |
| Income | 583 | 32.44 | 1159 | 20.76 | <0.0001 |
| Other | 58 | 3.23 | 202 | 3.61 | 0.8710 |
| Unknown | 65 | 3.62 | 141 | 2.53 | 0.0487 |
| Medicare eligibility (N, %) | |||||
| Not dually eligible | 1791 | 99.67 | 5558 | 99.53 | 0.9987 |
| Dually eligible | 5 | 0.28 | 24 | 0.43 | 0.6523 |
| Unknown | 1 | 0.05 | 2 | 0.04 | 0.9014 |
| Charlson comorbidity index score, mean (SD) | 0.67 | (1.38) | 0.65 | (1.36) | 0.5919 |
| Concomitant mental health and substance abuse comorbidities (N, %) | |||||
| Mental disorders | 382 | 21.26 | 1340 | 24.00 | 0.0456 |
| Drug or alcohol abuse | 338 | 18.81 | 856 | 15.33 | 0.0323 |
| Treatment naïve at index | 853 | 47.47 | 1366 | 24.46 | <0.0001 |
| Regimen length, mean (SD) | 348.17 | (259.32) | 433.46 | (351.50) | <0.0001 |
| Index medications (N, %) | |||||
| NRTI | 1797 | 100.00 | 5584 | 100.00 | – |
| NNRTI | 1797 | 100.00 | 1500 | 26.86 | <0.0001 |
| PI | – | – | 4064 | 72.78 | – |
| Kaletra at index | – | – | 1633 | 40.18 | – |
| Boosted PI at index | – | – | 1664 | 40.94 | – |
| Non-boosted PI at index | – | – | 767 | 18.87 | – |
| PE | – | – | 1712 | 30.66 | – |
| Other | – | – | 87 | 1.56 | – |
2+PPD, two or more pills per day; NNRTI, non-nucleoside/nucleotide reverse transcriptase inhibitor; NRTI, nucleoside/nucleotide reverse transcriptase inhibitor; PE, pharmacokinetic enhancer; PI, protease inhibitor; STR, once-daily single-tablet regimen.